title: Asenapine.
abstract: In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.
authors.affiliation: Herbert Y. Meltzer is at Vanderbilt University School of Medicine, Nashville, Tennessee 32712, USA. herbert.meltzer@vanderbilt.edu
authors.forename: Herbert Y
authors.initials: HY
authors.lastname: Meltzer
authors.forename: Argyris
authors.initials: A
authors.lastname: Dritselis
authors.forename: Uma
authors.initials: U
authors.lastname: Yasothan
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000503:physiopathology; D003986:Dibenzocycloheptenes; D017277:Drug Approval; D006576:Heterocyclic Compounds, 4 or More Rings / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; C522667:asenapine